Prostate Cancer:The early detection and early diagnosis of Prostate Cancer

The objective of the clinical trial is to compare findings achieved by traditional diagnostic procedures with those of the Medex Test in order to define specificity and accuracy of the Medex Test device as a diagnostic tool for early Prostate Cancer detection.

Status

Terminated

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12607000452493

Enrollment

200

Registered

2007-09-10

Start date

2007-09-03

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

The Medex Test device is a non-invasive and radiation free diagnostic tool. It is used for the assessment of functional abnormalities of the Prostate by electronic evaluation of the dermal-visceral connections. The principle of the Medex Test is based on detecting the change in the electrical impedance of certain dermal-visceral zones (DVZs) due to the organ’s disease. The Medex Test take around 20 minutes to conduct and the duration of the trial period is one year.

Study design

Allocation

Non-randomised trial

Intervention model

Parallel

Primary purpose

Diagnosis

Eligibility

Sex/Gender

Male

Age

18 Years to -2147483648 No limit

Healthy volunteers

Inclusion criteria

200 male patients with clinical symptoms of Prostate cancer and other related disorders.

Exclusion criteria

1.Amputees 2. Females 3.Local skin damage in areas of “Medex Test” examination. (i.e. hands and feet)

Outcome results